Literature DB >> 31337167

High-Voltage, Long-Duration Pulsed Radiofrequency on Gasserian Ganglion Improves Acute/Subacute Zoster-Related Trigeminal Neuralgia: A Randomized, Double-Blinded, Controlled Trial.

Chengfu Wan1, Dao-Song Dong1, Tao Song1.   

Abstract

BACKGROUND: Trigeminal postherpetic neuralgia is a severe neuropathic pain and often refractory to existing treatment, it develops secondary to herpes zoster-infected Gasserian ganglion. Therefore, it is important to prevent the transition of acute/subacute zoster-related pain to trigeminal postherpetic neuralgia. Despite numerous studies, the optimal intervention that reduces trigeminal postherpetic neuralgia incidence is still unknown.
OBJECTIVES: This study aimed to evaluate the efficacy and safety of high-voltage, long-duration pulsed radiofrequency (PRF) on the Gasserian ganglion in patients with acute/subacute zoster-related trigeminal neuralgia. STUDY
DESIGN: Prospective, randomized, double-blinded study.
SETTING: Department of Pain Medicine, the First Affiliated Hospital of China Medical University.
METHODS: Ninety-six patients with acute/subacute zoster-related trigeminal neuralgia were equally randomly assigned into 2 groups. The electrode needle punctured the Gasserian ganglion guided by computed tomography in every patient. High-voltage, long-duration PRF at 42°C for 900 seconds was applied in the PRF group (n = 48). It was also applied in the sham group (n = 48) without radiofrequency energy output. The therapeutic effects were evaluated using a visual analog scale (VAS) and the 36-Item Short Form Health Survey (SF-36) at different time points. The average dosage of pregabalin (mg/d) administrated within the first month after treatment was also recorded.
RESULTS: The postprocedure VAS scores in the PRF group were significantly lower than those in the sham group at different time points after treatment (P < 0.01). The SF-36 scores, which included physical functioning, physical role, bodily pain, general health perceptions, vitality, social function, emotional role, and the mental health index, were significantly improved at the sixth month after treatment in the PRF group compared with the sham group (P < 0.01). The average dosage of pregabalin administered (mg/d) within the first month after treatment was also significantly reduced in the PRF group compared with the sham group (P < 0.01). There were no bleeding, infection, or other severe side effects in both groups. LIMITATIONS: Single center study, relatively small number of patients.
CONCLUSIONS: High-voltage, long-duration PRF on the Gasserian ganglion is an effective and safe therapeutic alternative for patients with acute/subacute zoster-related trigeminal neuralgia. KEY WORDS: Pulsed radiofrequency, zoster-related trigeminal neuralgia, visual analog scale, 36-Item Short Form Health Survey.

Entities:  

Mesh:

Year:  2019        PMID: 31337167

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  13 in total

Review 1.  [Interdisciplinary position paper: the value of radiofrequency denervation in the treatment of chronic pain].

Authors:  Rudolf Likar; Johann Auer; Albert Chavanne; Wilfried Ilias; Michael Kern; Petra Krepler; Hans-Georg Kress; Ulrike Lischnig; Gernot Maurer; Oliver Sommer; Martin C Spendel; Siegfried Thurnher; Karl Wohak; Andreas Wolf; Michael Wölkhart
Journal:  Schmerz       Date:  2021-01-14       Impact factor: 1.107

2.  Comparison of the Efficacy of Short-term Peripheral Nerve Stimulation and Pulsed Radiofrequency for Treating Herpes Zoster Ophthalmicus Neuralgia.

Authors:  Xiaochong Fan; Huan Ren; Fuxing Xu; Zhongyuan Lu; Letian Ma; Cunlong Kong; Tao Wang; Huilian Bu; Wenqi Huang
Journal:  Clin J Pain       Date:  2022-11-01       Impact factor: 3.423

3.  Efficacy of Internal Heat Acupuncture Combined with High-Voltage Long-Duration Pulsed Radiofrequency on Subacute Postherpetic Neuralgia: A Retrospective Study.

Authors:  Yong Fei; Ming Yao; Bing Huang; Longsheng Xu; Beibei Liu
Journal:  Pain Res Manag       Date:  2022-06-10       Impact factor: 2.667

4.  Update on Interventional Management of Neuropathic Pain: A Delphi Consensus of the Spanish Pain Society Neuropathic Pain Task Force.

Authors:  Ancor Serrano-Afonso; Rafael Gálvez; Elena Paramés; Ana Navarro; Dolores Ochoa; Concepción Pérez-Hernández
Journal:  Medicina (Kaunas)       Date:  2022-04-30       Impact factor: 2.948

5.  Clinical Efficacy of Short-Term Peripheral Nerve Stimulation in Management of Facial Pain Associated With Herpes Zoster Ophthalmicus.

Authors:  Rui Han; Gangwen Guo; Yuncheng Ni; Ziyang Wang; Liuqing Yang; Jianping Zhang; Xuelian Li; Rong Hu; Dong Huang; Haocheng Zhou
Journal:  Front Neurosci       Date:  2020-09-23       Impact factor: 4.677

6.  Application of Nalbuphine in Trigeminal Ganglion Pulse Radiofrequency Surgery in Patients with Postherpetic Neuralgia.

Authors:  Song Wen; Qiu-Xia Xiao; Zhao-Qiong Zhu; Li Chen; Ying Li; Qi-Hua Ran; Song Cao; Liu-Lin Xiong
Journal:  Pain Res Manag       Date:  2021-03-01       Impact factor: 3.037

7.  Evaluation of the efficacy of unipolar and bipolar spinal dorsal root ganglion radiofrequency thermocoagulation in the treatment of postherpetic neuralgia.

Authors:  Jianjun Zhu; Ge Luo; Qiuli He; Ming Yao
Journal:  Korean J Pain       Date:  2022-01-01

8.  Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis.

Authors:  Junhyeok Kim; Min Kyoung Kim; Geun Joo Choi; Hwa Yong Shin; Beom Gyu Kim; Hyun Kang
Journal:  Korean J Pain       Date:  2021-10-01

9.  Short-Term Peripheral Nerve Stimulation Relieve Pain for Elder Herpes Zoster Ophthalmicus Patients: A Retrospective Study.

Authors:  Cheng-Fu Wan; Tao Song
Journal:  Neuromodulation       Date:  2020-10-15

10.  Therapeutic Efficacy of Ultrasound-Guided High-Voltage Long-Duration Pulsed Radiofrequency for Pudendal Neuralgia.

Authors:  Feng Ji; Shuzhuan Zhou; Caixia Li; Yongyan Zhang; Hua Xu
Journal:  Neural Plast       Date:  2021-07-30       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.